OTC Markets OTCPK - Delayed Quote USD

RemeGen Co., Ltd. (REGMF)

5.06
0.00
(0.00%)
At close: May 12 at 4:00:00 PM EDT
Currency in CNY All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
1,710,152
1,710,152
1,076,130
767,775
1,423,902
Cost of Revenue
342,796
342,796
253,136
269,939
67,163
Gross Profit
1,367,356
1,367,356
822,994
497,836
1,356,739
Operating Expense
2,738,184
2,738,184
2,325,340
1,551,915
1,053,655
Operating Income
-1,370,828
-1,370,828
-1,502,346
-1,054,079
303,084
Net Non Operating Interest Income Expense
-62,140
-62,140
5,052
54,786
38,025
Pretax Income
-1,468,362
-1,468,362
-1,511,229
-998,830
276,258
Tax Provision
0
0
0
0
0
Net Income Common Stockholders
-1,468,362
-1,468,362
-1,511,229
-998,830
276,258
Diluted NI Available to Com Stockholders
-1,468,362
-1,468,362
-1,511,229
-998,830
276,258
Basic EPS
-2.73
-2.73
-2.80
-1.88
0.57
Diluted EPS
-2.73
-2.73
-2.80
-1.88
0.57
Basic Average Shares
537,393.41
537,393.41
538,914.23
530,120.14
487,443.30
Diluted Average Shares
537,525.14
537,525.14
539,873.39
531,154.54
487,443.30
Total Expenses
3,080,980
3,080,980
2,578,476
1,821,854
1,120,818
Net Income from Continuing & Discontinued Operation
-1,468,362
-1,468,362
-1,511,229
-998,830
276,258
Normalized Income
-1,461,412
-1,461,412
-1,506,977
-999,823
276,599
Interest Income
10,239
10,239
28,143
61,543
43,348
Interest Expense
72,379
72,379
23,091
6,757
5,323
Net Interest Income
-62,140
-62,140
5,052
54,786
38,025
EBIT
-1,395,983
-1,395,983
-1,488,138
-992,073
281,581
EBITDA
-1,095,374
-1,095,374
-1,247,859
-805,702
402,053
Reconciled Cost of Revenue
342,796
342,796
253,136
269,939
67,163
Reconciled Depreciation
300,609
300,609
240,279
186,371
120,472
Net Income from Continuing Operation Net Minority Interest
-1,468,362
-1,468,362
-1,511,229
-998,830
276,258
Total Unusual Items Excluding Goodwill
-6,950
-6,950
-4,252
993
-341
Total Unusual Items
-6,950
-6,950
-4,252
993
-341
Normalized EBITDA
-1,088,424
-1,088,424
-1,243,607
-806,695
402,394
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 1/21/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

NYKD.OL Nykode Therapeutics AS
2.8500
+1.79%
 
IKT Inhibikase Therapeutics, Inc.
2.2300
+1.83%
 
9926.HK Akeso, Inc.
80.500
-0.49%
 
EVAX Evaxion Biotech A/S
1.6092
+8.00%
 
IOBT IO Biotech, Inc.
1.0000
-2.91%
 
ETNB 89bio, Inc.
7.80
-3.82%
 
GUBRA.CO Gubra A/S
384.80
+1.48%
 
2269.HK WuXi Biologics (Cayman) Inc.
23.150
0.00%
 
ABSI Absci Corporation
2.9600
+1.02%
 
BEAM Beam Therapeutics Inc.
18.05
-1.04%